The guideline is the first in a series that will focus on diagnosis, treatment, and care of Alzheimer disease and all other dementias, according to the association.
Data from Roche presented at AAIC 2025 highlight rapid amyloid clearance with investigational antibody and potential of pTau217 as blood-based rule-in and rule-out test.